ArticleERJ open research2026
Burden of eosinophilic granulomatosis with polyangiitis by disease phase and steroid-sparing effects of biologics: a real-world retrospective study in Europe.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of the study was to describe insights into real-world characteristics and clinical outcomes of patients with a history of eosinophilic granulomatosis with polyangiitis (EGPA) across Europe, stratified by disease phase and biologics use. Methods: This was a retrospective, physician-panel chart review study in patients with a history of EGPA from five European countries covering the period January 2015-August 2021 (GSK ID: 214661). Outcomes assessed included: baseline characteristics; treatment patterns; clinical outcomes and healthcare resource utilisation (HCRU), which were stratified Results: Overall, 407 patients were included: disease phase was identified for 381 patients (36 prodromal; 220 eosinophilic; 125 vasculitic); 185 patients received biologics, and 162 had pre-/post-biologics initiation periods identified. Patients in the vasculitic subgroup had the most comorbidities and clinical manifestations, and the greatest proportion of patients with hospitalisation Conclusion: Although the vasculitic subgroup showed the greatest disease severity, all subgroups demonstrated a substantial disease burden. Results also suggest biologics provide OCS-sparing effects and improve disease control in real-world settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.